MALVERN, Pa., Nov. 21, 2016 /PRNewswire/ -- NeuroStar announced today the launch of the largest depression outcomes registry ever in patients treated with its TMS (transcranial magnetic stimulation) therapy. The new outcomes registry is expected to exceed the total number of patients reported in STAR*D, which was the first federally funded, large-scale, long-term study directly comparing treatment strategies for patients with depression.
"In the long term, the research obtained from this registry has the potential to change the way we provide care to people with chronic depression," said Kenneth P. Pages, M.D., Medical Director, TMS of South Tampa. "The information collected over the years will equip physicians with case histories and the necessary research to tailor the most effective treatment plans. This, in turn, will allow us to better understand and ultimately meet the needs of these patients." The outcomes registry was established for the collection and analysis of data from patients with Major Depressive Disorder (MDD) who have been treated with NeuroStar Advanced Therapy. The intent of the registry is to further investigate and better understand the use of the therapy in a clinical setting. As such, data is expected to be collected from more than 6,000 depression patients across at least 100 different treatment facilities in the United States. "There are currently more than 740 NeuroStar providers across the U.S., with over one million treatments delivered to-date," said Mark Demitrack, MD, Chief Medical Officer for NeuroStar. "We are thrilled to roll out this registry to participating physicians and are striving for it to become the largest depression patient database ever. The primary objective of the multi-site, observational dataset is to report disease state outcomes for MDD patients treated with NeuroStar Advanced Therapy using validated clinical rating scales, thus enabling better patient care through easy, efficient outcomes analysis." NeuroStar is the leader in peer reviewed research, with 23 publications supporting the efficacy, safety, and durability of NeuroStar transcranial magnetic stimulation. In open-label clinical trials, 58% of people treated significantly responded, with 37% achieving complete remission of their depression symptoms. 1 Among people followed for 12 months after acute treatment, 68% retained their response. 2About NeuroStar Advanced TherapyNeuroStar is the established leader in transcranial magnetic stimulation (TMS) therapy, a non-invasive form of neuromodulation. It is backed by the largest clinical data set for MDD of any TMS Therapy. NeuroStar is the #1 physician-preferred TMS treatment for patients with MDD. With over 300 million covered lives, NeuroStar is widely reimbursed by most commercial and government health plans, including Medicare and Tricare. In addition, there are programs in place, such as NeuroStar Reimbursement Support, to help patients and providers obtain coverage and reimbursement for NeuroStar Advanced Therapy.